We investigated the transduction of HEK293T cells permissive to adeno-associated virus serotype 8 (AAV8) to understand the mechanisms underlying its endocytic processing. Results showed that AAV8 enters cells through clathrin-mediated endocytosis followed by trafficking through various endosomal compartments. Interestingly, compared to the relatively well-characterized AAV2, a distinct involvement of late endosomes was observed for AAV8 trafficking within the target cell. AAV8 particles were also shown to exploit the cytoskeleton network to facilitate their transport within cells. Moreover, the cellular factors involved during endosomal escape were examined by an in vitro membrane permeabilization assay. Our data demonstrated that an acidic endosomal environment was required for AAV2 penetration through endosomal membranes and that the cellular endoprotease furin could promote AAV2 escape from the early endosomes. In contrast, these factors were not sufficient for AAV8 penetration through endosomal membranes. We further found that the ubiquitin-proteasome system is likely involved in the intracellular transport of AAV8 to nucleus. Taken together, our data have shed some light on the intracellular trafficking pathways of AAV8, which, in turn, could provide insight for potentializing AAV-mediated gene delivery.
INTRODUCTION
Adeno-associated viruses (AAVs), as a family of parvoviruses, have been considered one of the most promising gene delivery vehicles owing to their relative nonpathogenicity and diverse tissue tropism with different AAV serotypes. [1] [2] [3] [4] Although different serotypes of AAVs have been shown to share a common genome structure, they have unique capsid proteins that can be recognized by different cell-surface receptors. 5 To date, more than 100 distinct primate AAV capsid sequences have been isolated, 6 and 12 primate serotypes of AAVs (AAV1 to AAV12) have been evaluated as recombinant gene therapy vectors. 7 Although AAV2, a relatively well-characterized AAV serotype, has been extensively investigated in clinical trials, 1, 8 many alternative serotypes are currently in preclinical and clinical development based on their different tissue tropisms and enhanced gene transfer efficiency. 2, 9, 10 Among them, AAV serotype 8 (AAV8) is uniquely able to efficiently transduce many different tissue types in vivo, including liver, 11 heart, 12 muscle, 12 brain and retinal pigment epithelium, making it particularly attractive for gene therapy applications. Recently, some clinical success has been demonstrated for the AAV8 vector in treatment of hemophilia B. 13 Although AAV8 vectors hold promise for human gene therapy, little is known about their intracellular trafficking pathways in target cells. Even for the relatively well-studied AAV2, the parameters governing its intracellular fate remain poorly understood.
For most viruses, cellular receptors define the host range and specific tissue tropism of different AAV serotypes. For example, heparan sulfate proteoglycan is a primary attachment receptor that mediates AAV2 binding to the surface of many cell types, 14 and a laminin receptor was reported to be an attachment receptor for AAV8. 15 Although it is generally believed that the cell tropism for AAVs is largely correlated with the abundance of their receptors and/or coreceptors on cell surfaces, multiple-step intracellular events appear to be another potential factor for determining the transduction efficiency of AAVs. 16 For example, it has been reported that AAV2 vectors bind efficiently to murine fibroblast cells and are internalized successfully, but the trafficking to nucleus is significantly impaired, thus limiting transgene expression in the cells. 17 Furthermore, a comparative study showed that a remarkably low efficiency of AAV2 transduction was obtained in endothelial cells compared with that of highly permissive cell types, even though the receptors for AAV2 are expressed in both situations. 18 This study revealed that AAV2 virions tended to accumulate in the Golgi area of permissive cell lines, but not endothelial cells, indicating that the intracellular trafficking of the virus can impact its transduction efficiency.
Many studies showed that AAV2 enters cells mainly via a clathrin-dependent pathway, and traffics through different endosomal compartments. [19] [20] [21] It has also been suggested that acidification inside the endosomal compartments is required for AAV transduction. 22, 23 When AAV2 was microinjected into the cytoplasm, which forced viruses to bypass a normal endocytic route, AAV2 particles failed to accumulate in the cell nucleus, indicating that endosomal processing may be crucial for nuclear transport and/or viral uncoating. 16, 24 However, the direct mechanism of endosomal transport/processing of AAV8 and, to a certain extent, AAV2 remains elusive. Furthermore, it is generally believed that AAVs must escape from endosomes into cytoplasm for subsequent transport to the nucleus. 7 Although a phospholipase A 2 domain in the N-terminus of VP1 is thought to be involved in endosomal escape, 25 a more detailed intracellular processing of AAV endosomal escape requires further study. Thus, understanding the fundamental basis of intracellular fate for various AAV serotypes will be beneficial in establishing methods to improve the efficiency of AAV-mediated gene therapy.
Therefore, the present study focused on unraveling the intracellular trafficking routes for AAV8, as compared with AAV2, by utilizing dynamic imaging of single viruses within target cells. In addition, the functional involvement of endocytic structures in the entry mechanism of AAV8 in living cells was investigated. This study identifies different requirements of endosomal trafficking for the productive transduction of these two AAV serotypes. To further investigate the process of endosomal escape, we developed an in vitro model to mimic different endosomal environments and endosomal protease activity. The resulting observations begin to define a paradigm for AAV8 entry in target cells which might provide a better understanding of the ratelimiting steps required for successful transduction of AAVs and could also increase the utility of these vectors for gene delivery applications.
RESULTS

Clathrin-dependent entry of AAV8
Clathrin-and caveolin-mediated pathways have been characterized as main routes of endocytosis of many viruses. It has been suggested that both AAV2 and AAV5 enter the cells via endocytosis, primarily through clathrin-coated pits. 26, 27 It was also suggested that AAV2 internalization depends on the large GTPase dynamin, 26 which is known for its role in forming clathrincoated vesicles from the plasma membrane. 28 To investigate the role of clathrin-or caveolin-dependent endocytosis in the entry of AAV8, we visualized the individual fluorescent dye-labeled AAV particles and endocytic structures (clathrin or caveolin) in HEK293T cells after different incubation time periods (0, 5, 10 and 30 min). As expected, a significant colocalization of AAV2 with the clathrin signals was observed after 5 min of incubation, while AAV8 particles were detected in the clathrin structures at 10 min after incubation (Figure 1a) . However, neither AAV8 nor AAV2 showed significant colocalization with caveolin during these time periods (Supporting Information, Figure S1 ). As shown in Figure 1b , the quantification of viral particles colocalized with clathrin at different incubation time periods suggested that colocalization of AAV2 particles with clathrin peaked at 5 min after incubation, whereas significant colocalization of AAV8 particles with clathrin was detected at 10 min after incubation, indicating that the internalization of AAV8 is relatively slower than that of AAV2 in HEK293T cells, most likely a consequence of different receptors/coreceptors involved in viral entry. The role of clathrin-dependent endocytosis in the entry of both AAV2 and AAV8 was further confirmed by drug-inhibition assays, as shown in Figure 1c . Chlorpromazine (CPZ) is known to block clathrin-mediated internalization by inhibiting clathrin polymerization, 29 while filipin is a cholesterol-binding reagent that can block the caveolin-dependent entry pathway. 30 It was shown that CPZ (10 mg ml À 1 ) significantly decreased the transduction of both AAV2 and AAV8 in HEK293T cells by 45.4% (Po0.01) and 56.9% (Po0.01), respectively. However, no significant inhibitory effect of filipin (10 mg ml À 1 ) was observed in either AAV2 or AAV8, which was further confirmed by the lack of enhanced inhibition effect of CPZ co-treated with filipin compared with that of CPZ treatment alone. These results suggested that both AAV2 and AAV8 enter cells through clathrin-dependent endocytosis and that caveolin might not be involved in early-stage viral entry. In addition, it was reported that dynamin, a GTPase protein involved in clathrin-mediated internalization, is required for AAV2 infection. 26 Thus, to investigate the functional involvement of dynamin for AAV8 entry, a dominant-negative mutant of dynamin (Dyn-K44A) was used to disable dynamin function. As shown in Figure 1d , the transduction of AAV8 was reduced by B40% in cells overexpressed with Dyn-K44A, as compared with that in wild-type dynamin-expressing cells. Taken together, these results demonstrated that AAV8 is internalized into cells through clathrincoated pits in a dynamin-dependent manner. Another inhibition experiment with bafilomycin A1 (BAF), a specific inhibitor of vacuolar proton ATPases, 31 showed that low pH-associated endosomal processes are involved in the productive infection of AAV2 and AAV8 in HEK293T cells. Moreover, depletion of cholesterol on target cell membrane with methyl-b-cyclodextrin had no effect on transduction, suggesting that cholesterol on the cell membrane might not be directly involved in the infection process of either AAV2 or AAV8 infection.
Differential involvement of endosomal trafficking of AAV2 and AAV8 It is generally believed that endosomal transport of viral particles is an important step of successful viral infection. Especially, processing of AAV2 virions through the endosomal compartments is thought to induce the conformational rearrangement of viral capsid for nucleus transport and uncoating. 24 Some studies suggested that AAV2 traffics through various endosomal compartments, including early, late and/or recycling endosomes. [20] [21] [22] The functional involvement of endosomes in AAV8 transduction, however, has not yet been reported. Thus, we conducted a colocalization experiment with early endosome antigen 1 (EEA1), cation-independent mannose 6-phosphate receptor (CI-MPR) and Rab11, as early, late and recycling endosome markers, respectively. After 15 min of incubation, the acquired images showed that B36% of AAV2 particles was observed in endosomes positive for EEA1 (Figure 2a, left) , but viruses were neither colocalized with CI-MPR nor Rab11. At 30 min, B29% of AAV2 particles were seen in the late endosomes (CI-MPR, Figure 2a , middle) and in the recycling endosomes (Rab11, Figure 2a , right), with a relatively lower level of colocalization between viral particles and EEA1 signals. These imaging results suggested that AAV2 might traffic from early endosomes to both late and recycling endosomes, which is consistent with the previous reports. 20, 21 However, imaging data showed differential involvement of endosomes for intracellular trafficking of AAV8, compared with that of AAV2. After a 45-min incubation, B50% of AAV8 particles were observed in endosomes positive for EEA1 (Figure 2b , left), and at 60 min, B26% of AAV8 particles were found in the recycling endosomes (Figure 2b , right) with a decreased level of colocalization between viral particles and early endosomes. However, no significant colocalization of AAV8 particles with CI-MPR was detected during any incubation period (15, 30, 45 , 60 min), suggesting that most AAV8 particles traffic through both early endosomes and recycling endosomes, but not through late endosomes. The quantification of AAV2 and AAV8 particles colocalized with EEA1, CI-MPR and Rab11 is shown in Figures 2c and d , respectively.
To further validate the confocal imaging results, the dominantnegative mutants of Rab proteins were employed to perturb either the early (Rab5), 32 late (Rab7) 33 or recycling (Rab11) 34 endosome function. HEK293T cells transfected with wild-type or the dominant-negative form of Rab5, Rab7 or Rab11 were transduced with AAV2 or AAV8. As shown in Figure 3a , expression of dominant-negative Rab5 reduced the transduction rate of AAV2 by B70%, as compared with the transduction of wild-type Rab5-expressing cells, indicating that the viral trafficking to early endosomes must be required for the AAV2 infection pathway. AAV2 transduction in HEK293T cells expressing dominant-negative Rab7 and Rab11 was also remarkably decreased by B40%
and B35%, respectively, compared with that in wild-typeexpressing cells, suggesting that AAV2 might traffic through both late and recycling endosomes for successful transduction. Similarly, the transduction of AAV8 was significantly decreased in cells transfected with dominant-negative Rab5 (B60%) or Rab11 (B40%), compared with that in wild-type-expressing cells (Figure 3b ), indicating that early and recycling endosomes are required for successful transduction of AAV8 in HEK293T cells. However, AAV8 transduction was not significantly affected by the Rab7-expressing dominant-negative mutant, again confirming that late endosomes might not be involved in the transduction pathway of AAV8, as observed in the confocal imaging results.
AAV8 transport mediated by microtubule and trans-Golgi network It has previously been reported that the microtubule network can facilitate the intracellular transport of AAV2 to the nucleus of cells. 35 To elucidate the functional involvement of microtubules in intracellular trafficking of AAV8, we first examined whether microtubule networks are involved in facilitating the migration of AAV8 within cells, and we conducted a colocalization experiment using a-tubulin-specific antibodies in cells. A remarkable number of viral particles were detected on microtubules (Figure 4a ), implying that AAV8 might travel along microtubule networks within cells. We further confirmed the imaging result by evaluating the effect of microtubule-disrupting reagents on viral transduction. AAV2, which is known to traffic through microtubule networks, was utilized as a positive control. Treatment of cells with nocodazole, which depolymerizes microtubules, remarkably reduced the transduction of AAV2 (B30%) and AAV8 (B35%), as compared with that in non-treated cells (Figure 4b ). This result was also confirmed by viral infection in HEK293T cells transfected with a small-interfering RNA (siRNA) to downregulate the expression of a-tubulin. As shown in Figure 4c , significantly lower transduction of AAV2 and AAV8 was obtained for cells transfected with a-tubulin-specific siRNA, as compared with that in cells transfected with control siRNA. These lines of evidence suggest that microtubule networks have an important role in intracellular trafficking and successful infection of AAV8.
It has also been suggested that AAV2 and AAV5 might traffic to the trans-Golgi network before translocation into nucleus of the cell. 18, 36 Although it remains unclear which pathways are utilized for transport of AAV virions to trans-Golgi, it is likely that the transport to Golgi compartment is either from the late endosome facilitated by Rab9 or from the perinuclear recycling endosome that occurs through a Rab11-facilitated mechanism. 16 To investigate the role of trans-Golgi network in the intracellular trafficking of AAV8, three-dimensional (3-D) image reconstruction was used to evaluate whether dye-labeled AAV particles had a tendency to accumulate in trans-Golgi compartments. As expected, most AAV2 particles were detected in Golgi compartments in HEK293T cells after 4 h of incubation at 37 1C (Figure 4d, upper) . Many AAV8 particles were also observed in trans-Golgi compartments, albeit at a relatively lower level of accumulation compared with AAV2 (Figure 4d, lower) , suggesting that the trans-Golgi network might be involved in the infection process of AAV8.
In vitro study of endosomal escape with low pH and furin It has been proposed that nonenveloped viruses have developed strategies to overcome various membranous barriers in the process of escaping from endosomes to cytoplasm. 37 Among the membrane penetration processes, a conformational change in viral structure is an essential step, enabling viral particles to be transported across the membrane by interaction with such cellular cues as low pH or proteases. 37 For example, a low-pH endosomal environment was reported to trigger the destablilization of the adenovirus capsid, thus causing the release of internal protein VI, in turn leading to the successful penetration of adenovirus through disruption of the endosomal membrane. 38 It has been proposed that parvovirus utilizes the phospholipase A 2 domain located at the N-terminus of coat protein VP1 to break the endosomal membranes. 39 However, the cellular factors and mechanisms involved in AAV penetration of the endosomal membranes, even for the relatively well-characterized AAV2, are poorly understood.
To understand the requirement of cellular factors involved in the endosomal escape of AAV2 and AAV8, we designed a membrane penetration assay using a transwell; the lipid bilayer membrane was formed on the bottom of the upper compartment to mimic endosomal membranes. This assay enabled us to quantify the viruses transporting through the membrane toward the lower compartment when the viruses were exposed to the different conditions in the upper compartment. We first performed an assay to examine the role of pH in endosomal escape. Viruses were treated with PBS at different pH values (7.4, 6.0 or 5.0) in the upper compartment to mimic different endosomal environments. The number of viral genome copies that were transported across the membrane to the lower compartment was then measured by quantitative PCR (qPCR). As shown in Figure 5a , a moderate enhancement of the genome copy number was observed in AAV2 pretreated with buffer of pH 6.0, as compared with that of the virus treated with pH 7.4 as a control, indicating that an early endosomal environment (BpH 6.0) might be beneficial for AAV2 escape. In addition, treatment with PBS at pH 5.0 allowed significantly more AAV2 particles to move across the membrane, as compared with that of the virus treated with pH 7.4 or pH 6.0 PBS, indicating that the increasingly acidic environment found in late endosomes favors membrane Infectious entry pathway of AAV8 Y Liu et al penetration of AAV2. However, no significant change was observed in the genome copy number of AAV8 treated with PBS at different pH values, as shown in Figure 5b , indicating that low pH alone is not sufficient for the AAV8 viral penetration from endosomes and that, consequently, other cellular factors might be required for AAV8 escape.
Therefore, we investigated other cellular factors that might be involved in endosomal escape of AAV2 and AAV8. It was reported that the cleavage of the papillomavirus capsid protein L2 by furin, which is known to be required for endosomal escape of various bacterial toxins, is necessary for papillomavirus infection. 40 Furin is a cellular endoprotease that cleaves proproteins at clusters of basic residues, typically at the R-X-K(R)-R site, 41 which is also found in both AAV2 and AAV8 capsid proteins (VP1, VP2 and VP3) (Figure 5c ), suggesting that furin might have a role in virus endosomal escape. In addition, it is believed that furin is mainly localized at the trans-Golgi network, the cell surface and the early endosomes. 42 To examine whether furin cleavage of the virus capsid protein could promote endosomal escape of AAV2 and AAV8, viruses were treated with furin in PBS at different pH values to mimic the different environments where furin activity occurs. Interestingly, furin treatment at pH 6.0 remarkably enhanced AAV2 membrane penetration, while no significant enhancement of virus penetration was observed at pH 7.4 or pH 5.0 (Figure 5d ). On the other hand, co-incubation with furin inhibitor completely eliminated such enhanced penetration (Figure 5d ). This result indicates that furin cleavage of the AAV2 capsid in early endosomes might facilitate endosomal escape. However, among the three different pH environments tested, no significant effect of furin treatment on AAV8 penetration was observed (Figure 5e ), indicating that furin might not be involved in AAV8 endosomal escape. To further confirm the functional involvement of furin in virus infection, HEK293T cells treated with the furin inhibitor were transduced with AAV2 or AAV8 particles carrying a green fluorescent protein (GFP) reporter gene, and the resulting GFP expression was analyzed by fluorescence-activated cell sorting. The result showed that treatment with the furin inhibitor decreased B20% of the transduction efficiency of AAV2 compared with transduction in non-treated cells (Figure 5f ), indicating that the early endosomes might be one of potential sites of the endosomal escape. However, the moderate reduction (B20%) of transduction efficiency with the furin inhibitor also indicates that most virus particles are likely travel further to late or recycling endosomes or Golgi compartments without escaping from the early endosome. As also shown in this experiment, no inhibitory effect by furin inhibitor was observed for AAV8 transduction, again confirming that furin might not be involved in AAV8 escape from endosomes ( Figure 5f ). Taken together, endosomal acidity appears to be essential for the AAV2 escape, and furin cleavage of the AAV2 capsid protein could promote viral penetration through the endosome membrane. These experiments also suggested that other cellular factors are most likely required for AAV8 endosomal escape.
Translocation of AAV8 facilitated by the ubiquitin-proteasome pathway It is generally believed that AAV2 traffics to nucleus after escaping from various endosomes. During this process, the likely involvement of the ubiquitin-proteasome pathway in the AAV2 entry process was reported. 43 It has been demonstrated that proteasome inhibitor (MG132) could significantly increase the level of capsid ubiquitination of both AAV2 and AAV5. 43 However, the involvement of the ubiquitin-proteasome pathway in the intracellular processing of AAV8 remains unknown. Here, we first investigated the role of the ubiquitin-proteasome system in AAV8 transduction via the drug-inhibition assay. As shown in Figure 6a , treatment of cells with MG132 remarkably augmented the transduction efficiency of AAV8 in HEK293T cells, a finding also observed in AAV2.
To further examine whether enhanced transduction in the presence of MG132 resulted from the direct effect of blocking AAV8 degradation, we measured the total intracellular genome copy of viruses in infected cells with or without MG132 treatment. Interestingly, no significant change was detected in the total viral genome copy number of AAV8 between cells treated with MG132 and non-treated cells (Figure 6b) . A similar result was also found in AAV2, which is consistent with previous reports. 43, 44 Further study on the quantification of the viral genome copies isolated from the cytoplasmic and nuclear fractions of the infected cells demonstrated that the accumulation of viral genomes of AAV8 in the nucleus was significantly enhanced in the presence of MG132 (Figure 6c) , implying that the modulation of ubiquitinproteasome system could alter the intracellular fate of AAV8, especially in terms of promoting the nuclear translocation of AAV8 particles. Although the detailed mechanism of AAV8 intracellular processing in the presence of the proteasome inhibitor remains to be elucidated, this study shows that the level of the viral capsid ubiquitination could be important in modulating the intracellular processing of AAV8. Although different viral capsid proteins and their receptors/coreceptors could contribute to differential infectivity of the viruses, distinct intracellular fate also appears to be another critical element for determining their infection efficiency. In this study, we performed a series of experiments to investigate the differences in the intracellular behavior of AAV8, as compared with that of AAV2, aiming to unveil the possible biology responsible for the unique properties of AAV8. For the sake of directly comparing entry mechanism and intracellular transport between AAV8 and AAV2, we chose the AAV8 capsid encapsulating the AAV2 genome as the AAV8 particles to minimize the possible effects caused by their different viral genomes. By using drug inhibition, dominant-negative mutant and colocalization experiments, this study demonstrated that AAV8 is internalized into cells via clathrin-coated pits in a dynamindependent manner. Interestingly, colocalization results suggested that AAV8 exhibited a slower kinetics of clathrin-associated internalization as compared with AAV2, which most likely results from different primary attachment receptors involved in the virus entry of AAV2 and AAV8. 14, 15 It has been generally believed that vectors using clathrinmediated endocytosis subsequently experience an acidic environment in the early endosomes. 45 Through colocalization studies using defined endosomal markers, which were further confirmed by the studies with dominant-negative mutants of Rab constructs, we have shown that AAV8 requires trafficking in both the early and recycling endosomes for successful infection of HEK293T cells. In contrast, AAV2 vector was shown to transport through the early, late and recycling endosomes, which is consistent with previous studies. 20, 22 Although the detailed molecular mechanism underlying the differential endosomal sorting processes remains unclear, studies have demonstrated that the distinct endosomal trafficking could be the result of viruses binding to different attachment receptors. 20 This observation suggests that our data confirming differential involvement of late endosomes in AAV2 Infectious entry pathway of AAV8 Y Liu et al and AAV8 trafficking could also be a product of the different cellular receptors involved in virus entry that are targeted to distinct intracellular compartments in the cell. In addition, early endosomes have been considered as a sorting station where cargos can be directed to several intracellular destinations. 46 Some elements, including geometric constraint (that is, membrane-bound and fluidic phase components) 47, 48 and lipid composition, 49, 50 have been proposed to have a crucial role in sorting. Although the sorting process itself still remains unclear, different surface-charge of AAV2 and AAV8 capsid and/or differentially exposed hydrophobic residues on virus capsid triggered by a conformational change in early endosomes could also possibly influence the distinct endosomal sorting between AAV2 and AAV8.
Following viral trafficking through various endosomal compartments, retrograde transport of AAV2 to the Golgi apparatus has been observed in our imaging study. Although the detailed pathways utilized for viral transport to trans-Golgi remain elusive, AAV2 particles sorted toward late endosomes from early endosomes are believed to be further trafficked to Golgi compartments through a Rab9-facilitated pathway, while virions destined to perinuclear recycling endosomes are likely transported to the Golgi through a Rab11-dependent mechanism. 16, 18 Similarly, accumulation of AAV8 particles in trans-Golgi compartments was observed in this study. As our result indicated that late endosomes might not be involved in the transduction pathway of AAV8, viral transport to the Golgi compartments could possibly occur through the perinuclear recycling endosome-facilitated mechanism.
Viral escape from the endosomal membranes to cytosol in the target cell has been considered a key barrier against cell entry. Therefore, different viruses are known to exploit different strategies to exit endosomes. For nonenveloped viruses, it has been hypothesized that viruses exploit cellular factors that can trigger the conformational change of viral capsid proteins, leading to membrane disruption to escape from endosomes. 37, 51 For instance, a low-pH environment was suggested to trigger the conformation change of parvoviruses via the activation of phospholipase A 2 that is located at the N-terminus of capsid protein VP1 for disrupting endosomal membranes. 25, 52 Our in vitro membrane penetration assays suggested that exposure to the low acidic endosomal environment might be one of cellular factors triggering AAV2 penetration. However, although our druginhibition assay with BAF indicated that AAV8 requires a low-pH environment for productive infection in HEK293T cells, it appeared that acidification alone is not sufficient to promote AAV8 penetration through the endosome membrane. These results suggest that AAV8 must travel at least to the acidic endosomal compartments, and then subsequently, additional endosomal processing of viruses with other cellular factors is required for triggering the endosomal escape of AAV8. One study indicated that acidification is essential but not sufficient for canine parvovirus transduction demonstrated by microinjecting Infectious entry pathway of AAV8 Y Liu et al particles pretreated at pH 5.0, 53 which was designed for bypassing the endosomal process, suggesting that the endosomal processing may have a critical role in priming the virus other than just acidification for viral uncoating and/or subsequent transduction steps.
In addition to low pH, proteases have been reported to have a role in the penetration of viral particles from the endosomal membrane. 37, 54 Moreover, furin has been identified to initiate membrane penetration of papillomavirus by cleaving the N-terminus of L2 protein of the virus. 40 Furthermore, the typical cleavage site for furin is found in both AAV2 and AAV8 capsid proteins, suggesting that furin could be involved endosomal escape during AAV entry. In vitro assay results suggested that furin could likely foster the process of viral penetration from the early endosomal membrane for AAV2. As we observed only a modest reduction (B20%) of AAV2 transduction in cells treated with furin inhibitor, it raised the possibility that the early endosome might not be the main site of AAV2 endosomal escape and that AAV2 virions could escape the endocytic pathway through multiple routes (for example, late or recycling endosomes or Golgi compartments). Furin does not appear to be involved in AAV8 viral escape, suggesting that other cellular factors must be required. One study previously identified endosomal proteases, cathepsins B and L, as an uncoating factor of AAV2 and AAV8, suggesting that the partial disassembly of the viral capsid triggered by those proteases is essential for AAV2-and AAV8-mediated transduction of mammalian cells. 55 The functional involvement of cathesins B and L in AAV8 endosomal escape remains to be further studied.
Once AAV has escaped from the endosome, it must be transported into the nucleus before uncoating. Various signaling pathways might be involved in this process. By inhibiting proteasome function during virus infection, it has been shown that the ubiquitin-proteasome pathway has a role in AAV2 transduction. 44 In this study, we demonstrated that proteasome inhibitor MG132 enhanced gene transfer efficiency mediated by either AAV2 or AAV8. This enhanced transduction is unlikely a result of blocking the degradation of AAV in the presence of proteasome inhibitor MG132. Instead, the augmented transduction is probably a product of enhanced uptake of viruses to the nucleus of the cell upon inhibition of the proteasome, suggesting that the modulation of the ubiquitin-proteasome system could promote uptake of AAV8 to the nucleus of target cells.
To summarize, this comparative study has provided important clues into the intracellular trafficking pathways involved in AAV8 transduction, thus improving our understanding of molecular mechanisms that might establish a basis for designing more efficient gene transfer strategies and potentializing AAV-mediated gene therapy. 
MATERIALS AND METHODS
AAV production
Recombinant AAV2 or AAV8 vectors were produced in HEK293 cells as previously described. 56 Forty 15-cm dishes of subconfluent HEK293 cells were triple-transfected with 650 mg each of AAV2 or AAV8 cis-plasmid and AAV2 or AAV8 trans-plasmid containing the rep and cap genes and 1300 mg of the adenovirus helper plasmid pDF6 using the calcium phosphate precipitation method. For AAV2 vectors, after an additional 16 h of incubation, the medium was replaced with fresh media. The cells were harvested at 3 days post-transfection, followed by three cycles of freeze and thaw. For AAV8 vectors, the virus supernatants were harvested every 12 h and replaced with fresh medium for 7 days. AAV2 or AAV8 viruses were then purified by cesium chloride gradient density centrifugation 57 at 25 000 r.p.m. and 15 1C for 20 h (Optima L-90 K Ultracentrifuge, SW-28 rotor, Beckman Coulter, Brea, CA, USA). Viral particles recovered from the first round ultracentrifugation were pooled and subjected to an isopycnic separation by a second cesium chloride centrifugation at 13 000 r.p.m.and 15 1C for 20 h in a SW-32 Ti Infectious entry pathway of AAV8 Y Liu et al rotor. Fractions containing AAV2 or AAV8 determined by refractive index were further desalted in PBS using an Amicon Ultra 100 000 MWCO centrifugal filter device (Millipore, Billerica, MA, USA).
Plasmids
The plasmid encoding the dominant-negative mutant of DsRed-Rab7 (Rab7T22N) was generated by site-directed mutagenesis as described. 58 The constructs for wild-type and dominant-negative forms of DsRed-Rab5, DeRed-Rab7, DeRed-Rab11 and GFP-a-tubulin were obtained from Addgene (Cambridge, MA, USA). The dominant-negative form (Dyn-K44A) of DsRed-dynamin was provided by Dr Okamoto (Department of Pharmacology and Pharmaceutical Sciences, University of Southern California). The negative control siRNA and a-tubulin siRNA were purchased from Santa Cruz Biotechnology Inc. For viral transduction with siRNA-treated cells, HEK293T cells were seeded in a 24-well dish overnight at 37 1C. The seeded cells were transiently transfected with either a control or a-tubulin-specific siRNA. Twenty-four hour after transfection, the treated cells were spin-infected by AAV2 or AAV8. The percentage of GFP-positive cells was analyzed by flow cytometry at 72 h post-infection. To investigate the role of furin inhibitor in AAV transduction, HEK293T cells were plated in a 24-well plate overnight followed by spin infection. Furin inhibitor (250 mM) was added with viral particles. GFP expression was analyzed 3 days post-infection.
Virus transduction
Dye labeling of AAV
To label AAV2 and AAV8 particles with organic dyes, purified AAV (1 Â 10 10 particles) were incubated with 50 nmol of Alexa488-TFP ester (Invitrogen) for 2 h in 0.1 M sodium bicarbonate buffer (pH ¼ 9.3). After a 2-h incubation, the reaction was stopped, and unbound dye molecules were removed via buffer exchange into PBS (pH ¼ 7.4), using a Zeba desalting spin column (Thermo Fisher Scientific).
Confocal imaging
Fluorescence images were acquired on a Yokogawa spinning-disk confocal scanner system (Solamere Technology Group, Salt Lake City, UT, USA) using a Nikon eclipse Ti-E microscope (Nikon, Melville, NY, USA) equipped with a Â 60/1.49 Apo TIRF oil objective and a Cascade II: 512 EMCCD camera (Photometrics, Tucson, AZ, USA). An AOTF (acousto-optical tunable filter) controlled laser-merge system (Solamere Technology Group Inc., Salt Lake City, UT, USA) was used to provide illumination power at each of the following laser lines: 491, 561 and 640 nm solid state lasers (50 mW for each laser). For the intracellular trafficking studies, HEK293T cells were seeded on polylysine-coated glass bottom dish (MatTek Corporation, Ashland, MA, USA) overnight at 37 1C and were then incubated with dye-labeled AAV2 or AAV8 (B2000 viral genome copies per cell) for 30 min at 4 1C to synchronize infection. The cells were washed with cold PBS to remove unbound viruses and were then shift to 37 1C to initiate virus internalization for different indicated incubation periods. The dish was then rinsed, fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-100 and then immunostained with the corresponding antibodies specific to clathrin, caveolin-1, EEA1, CI-MPR, Rab11, TGN or microtubules, or counterstained with TO-PRO-3 (Invitrogen).
The Z stack images of cells were imaged at 0.4 mm intervals and analyzed by the Nikon NIS Element software.
In vitro model of endosomal membrane
Twenty-fourth transwell plates with 0.45 mm pore filters on the bottom of the upper compartment were used to study the endosomal escape of AAVs. A planar lipid bilayer was formed by applying 5 ml of 1% L-a-phosphatidycholine (Sigma-Aldrich, St Louis, MO, USA) on porous filters of the upper compartment. Either AAV2 or AAV8 (10 8 genome copies) in PBS with indicated pH values was incubated in the upper transwell compartment for 24 h. For the furin study, either AAV2 or AAV8 in the upper compartment was incubated with 4 units of furin with or without furin inhibitor (final concentration 250 mM). The vectors transferred to the lower compartment with pH 7.4 PBS were collected, and intracellular genomes were extracted and quantified by qPCR assay.
Subcellular nuclear/cytosol fractionation
Approximately 2 Â 10 5 cells per well were seeded in a 24-well dish and allowed to adhere overnight. The cells were treated with MG132 for 30 min, followed by either mock infection or infection with AAV2 or AAV8 for 20 h. The cells were washed once with PBS, trypsinized for 3 min and then centrifuged down. Then Nuclear/Cytosol Fractionation Kit (BioVision, Inc., Mountain View, CA, USA) was employed to separate the cytoplasmic and nuclear extracts from infected cells in the presence or absence of MG132. All procedures were performed at 4 1C. Extracts were stored at À 80 1C until the qPCR assay was performed.
Quantification of genome copies by PCR Viral DNA was extracted using the QIAamp MinElute Virus Spin Kit (Qiagen, Valencia, CA, USA), according to the manufacturer's protocol. Quantitative PCR was performed on the Bio-Rad MyiQ real-time system (Bio-Rad, Hercules, CA, USA) using a pair of primers specific for the GFP transgene: 5 0 -GACATCATGAAGCCCCTTGAG-3 0 (forward) and 5 0 -GGTGGTCGAAATTCA GATCAAC-3 0 (reverse).
